Covadonga Paneda, PhD

Chief Development Officer at Altamira Therapeutics

Dr. Covadonga Pañeda, Ph.D. has over 15 years of experience in leadership and management of biotechnology companies acquired through various roles in drug development, contract research organizations and in the biotech venture capital sector in Europe. Before joining Altamira in April 2022, she spent seven years managing Sylentis S.A R&D efforts, a clinical stage RNAi biopharmaceutical company, two years leading the translational activities of newly founded companies in the academic sector including Isquaemia Biotech and Mirnax Biosens; and most recently, she served as Director of Development at LiMM Therapeutics, a neuroimmune biopharmaceutical company.

Dr. Pañeda holds a Ph.D. in Biochemistry and Molecular Biology from the Faculty of Medicine at Universidad Autónoma, Madrid, Spain, and a Master of Management of Biotechnology Companies awarded by Fundación Genoma España, Madrid, Spain.